|
CMDX is proud to offer HemeScan™ for chronic lymphocytic leukemia (CLL), the first of our HemeScan™ suite of BAC (Bacterial Artificial Chromosome) array CGH (Comparative Genomic Hybridization) based tests for hematological malignancies. HemeScan™ is designed to detect all of the known recurrent genomic abnormalities associated with prognosis in CLL while simultaneously providing a global view of the tumor genome. This test is now available to our physicians and patients.
"The HemeScan™ test has proven to be a valuable and reliable clinical tool for the management of hematological malignancies (leukemia and lymphomas) and solid tumors characterized by unbalanced chromosomal rearrangements," says Dr. Shelly Gunn, M.D., Ph.D., Medical Director of Combimatrix Molecular Diagnostics (CMDX), "The HemeScan™ test is a comprehensive test enabling prognosis at the time of diagnosis in the treatment and care of CLL patients. The test provides prognostic marker precision with simultaneous diagnostic monitoring of the entire genome in CLL."
Talk with your physician about ordering the HemeScan™ test to help determine what kind of CLL you have.
Recent scientific publications demonstrate the importance of detecting genome-wide abnormalities in CLL when evaluating whether a patient has high, intermediate or low risk disease. Below are some recent studies and news reports on CLL.
Articles of Interest About CLL
Cancer Genetics and Cytogenetics
Clonal evolution in chronic lymphocytic leukemia
Comparative Genomic Hybridization Arrays in Clinical Pathology
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL
Tools for molecular risk-stratification for clinical purposes: CLL as a prototype
Links About CLL
http://bloodjournal.hematologylibrary.org/cgi/reprint/103/4/1202?ck=nck
http://clltopics.org/PI/Type.htm
http://clltopics.org/PI/Murky.htm
http://www.leukemia-lymphoma.org/all_page.adp?item_id=7059
|
